Final answer:
Omnipaque-240 is the correct contrast media approved for intrathecal use.
Step-by-step explanation:
The contrast media approved for intrathecal use is Omnipaque-240 (b). Intrathecal administration involves injecting contrast media into the spinal canal, particularly into the subarachnoid space, to enhance diagnostic imaging, such as in a myelogram. It is essential that only contrast agents specifically indicated for intrathecal injection are used, as the use of non-approved agents can result in serious adverse reactions. Omnipaque-240 is an iso-osmolar, non-ionic water-soluble contrast agent with approval for this use. Other formulations, like Omnipaque-350, may be used for different indications or routes of administration, but not for intrathecal injection.